阿比特龙、多西他赛或安慰剂联合雄激素剥夺疗法治疗激素敏感性晚期前列腺癌的成本效益分析数据集

数据集获取（Figshare）

• 源站标题：Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
• DOI：10.6084/m9.figshare.14322312.v1
• 发布日期：2021-03-26
• 文件数：7 个
• 文件总体积：1.58 MB
• 源站页面：https://scielo.figshare.com/articles/dataset/Cost-effectiveness_analysis_of_abiraterone_docetaxel_or_placebo_plus_androgen_deprivation_therapy_for_hormone-sensitive_advanced_prostate_cancer/14322312

命令行下载

curl -L -o "2317-6385-eins-17-02-eGS4414-gf01.jpg" "https://ndownloader.figshare.com/files/27283587"
curl -L -o "2317-6385-eins-17-02-eGS4414-gf02.jpg" "https://ndownloader.figshare.com/files/27283590"
curl -L -o "2317-6385-eins-17-02-eGS4414-gf03.jpg" "https://ndownloader.figshare.com/files/27283593"
curl -L -o "2317-6385-eins-17-02-eGS4414-gf04.jpg" "https://ndownloader.figshare.com/files/27283596"
curl -L -o "2317-6385-eins-17-02-eGS4414-gf05.jpg" "https://ndownloader.figshare.com/files/27283599"
curl -L -o "Table_1.xls" "https://ndownloader.figshare.com/files/27283602"
curl -L -o "Table_2.xls" "https://ndownloader.figshare.com/files/27283605"

文件清单

• 2317-6385-eins-17-02-eGS4414-gf01.jpg（156.74 KB）
• 2317-6385-eins-17-02-eGS4414-gf02.jpg（458.35 KB）
• 2317-6385-eins-17-02-eGS4414-gf03.jpg（309.48 KB）
• 2317-6385-eins-17-02-eGS4414-gf04.jpg（364.07 KB）
• 2317-6385-eins-17-02-eGS4414-gf05.jpg（279.67 KB）
• Table_1.xls（5.63 KB）
• Table_2.xls（5.63 KB）

文件总体积 1.58 MB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

ABSTRACT Objective To evaluate the cost-effectiveness of the addition of chemotherapy or abiraterone to androgen deprivation. Methods We developed an analytical model to determine the cost-effectiveness of the addition of docetaxel or abiraterone versus androgen deprivation therapy alone. Direct and indirect costs were included in the model. The effects were expressed in Quality-Adjusted Life Years adjusted for side effects. Results Compared to androgen deprivation therapy alone, the addition of chemotherapy and of abiraterone generated 0.492 and 0.999, respectively, in Quality-Adjusted Life Years. Abiraterone led to a Quality-Adjusted Life Years gain of 0.506 compared to docetaxel. The incremental costs per Quality-Adjusted Life Years were R$ 133.649,22 for docetaxel, R$ 330.828,70 for abiraterone and R$ 571.379,42 for abiraterone compared to docetaxel, respectively. Conclusion The addition of chemotherapy to androgen deprivation therapy is more cost-effective than the addition of abiraterone to androgen deprivation therapy. However, discounts on abiraterone cost might improve cost-effectiveness.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.14322312.v1（source: https://scielo.figshare.com/articles/dataset/Cost-effectiveness_analysis_of_abiraterone_docetaxel_or_placebo_plus_androgen_deprivation_therapy_for_hormone-sensitive_advanced_prostate_cancer/14322312）。